ProPhase Labs (PRPH) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRPH, but not buy additional shares or sell existing shares.
View PRPH analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1-year target prices for ProPhase Labs' shares. Their PRPH share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price.
View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts.

ProPhase Labs' stock was trading at $9.63 at the beginning of the year. Since then, PRPH stock has decreased by 16.1% and is now trading at $8.08.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our PRPH earnings forecast.

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its earnings results on Tuesday, March, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.10. The firm earned $21.82 million during the quarter, compared to the consensus estimate of $20.53 million. ProPhase Labs had a net margin of 6.91% and a trailing twelve-month return on equity of 10.05%.

First Trust Dow Jones Select Microcap Index Fund holds 35,105 shares of PRPH stock, representing 0.18% of its portfolio.

2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.12%), BlackRock Inc. (0.64%), Acadian Asset Management LLC (0.58%), American Century Companies Inc. (0.48%), Bank of New York Mellon Corp (0.38%) and State Street Corp (0.24%). Insiders that own company stock include Jason Michael Barr and Ted William Karkus.
View institutional ownership trends.

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRPH stock can currently be purchased for approximately $8.08.

ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $138.81 million and generates $122.65 million in revenue each year. The company earns $18.46 million in net income (profit) each year or $0.41 on an earnings per share basis.

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for the company is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at ir@prophaselabs.com, or via fax at 215-345-5920.